Results 81 to 90 of about 27,094 (219)

BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation

Frontiers in Immunology, 2019
Group 2 innate lymphoid cells (ILC2) increase in frequency in eczema and allergic asthma patients, and thus represent a new therapeutic target cell for type-2 immune-mediated disease.
Bernhard Kerscher, Jillian L. Barlow, Batika M. Rana, Helen E. Jolin, Mayuri Gogoi, Michelle A. Bartholomew, Deepali Jhamb, Ashutosh Pandey, David F. Tough, Antoon J. M. van Oosterhout, Andrew N. J. McKenzie   +10 more
doaj   +1 more source

Challenges and Pitfalls to Diagnosing NUTM1‐Rearranged Neoplasia of the Pancreas by Cytology and Ancillary Studies

Diagnostic Cytopathology, EarlyView.
ABSTRACT Fine‐needle aspiration cytology specimens are frequently utilized for ancillary studies to identify diagnostic and prognostic information. This case highlights diagnostic pitfalls and challenges in diagnosing NUTM1‐rearranged neoplasia on pancreatic cytology.
Terrance J. Lynn
wiley   +1 more source

Effect of Bromodomain and Extraterminal Inhibitors with Different Bromodomain Selectivity on Mesenchymal Stem Cells

International audienceAbstract This study examines the influence of bromodomain and extraterminal (BET) inhibitors with different selectivity for bromodomains on human mesenchymal stem cells (hMSCs).
Ebara, Mitsuhiro, Uto, Koichiro, Wong, Yung-Sing, Tanimoto, Riho   +3 more
core   +1 more source

A novel carboxamide bromodomain inhibitor attenuates osteoarthritis via epigenetic repression of NF-κB and MAPK signaling

Frontiers in Immunology
Bromodomains are epigenetic readers that modulate gene expression linked to inflammation and cartilage degeneration. Emerging evidence suggests their dysregulation plays a pivotal role in osteoarthritis (OA) pathogenesis, making them promising ...
Hyemi Lee, Seong Jae Han, Subin Ok, Kwang Min Lee, Seungseok Choi, Injoo Yoon, Somang Choi, Jina Kim, Serim Ryu, Min-Hee Son, In-Hyun Lee, Chanmi Cho, Siyoung Yang   +12 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign

Molecules
A 3D structure-based pharmacophore model built for bromodomain-containing protein 4 (BRD4) is reported here, specifically developed for investigating and identifying the key structural features of the (+)-JQ1 known inhibitor within the BRD4 binding site.
Ester Colarusso, Erica Gazzillo, Eleonora Boccia, Stefania Terracciano, Ines Bruno, Giuseppe Bifulco, Maria Giovanna Chini, Gianluigi Lauro   +7 more
doaj   +1 more source

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

eLife, 2016
Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression.
Andrew R Conery, Richard C Centore, Adrianne Neiss, Patricia J Keller, Shivangi Joshi, Kerry L Spillane, Peter Sandy, Charlie Hatton, Eneida Pardo, Laura Zawadzke, Archana Bommi-Reddy, Karen E Gascoigne, Barbara M Bryant, Jennifer A Mertz, Robert J Sims III   +14 more
doaj   +1 more source

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma [PDF]

, 2014
PurposeMYC-amplified medulloblastomas are highly lethal tumors. Bromodomain and extraterminal (BET) bromodomain inhibition has recently been shown to suppress MYC-associated transcriptional activity in other cancers.
Weiss, William A.,, Cho, Yoon-Jae, Swartling, Fredrik J, Bolin, Sara,, Cheshier, Samuel H., Paolella, Brenton R., Wechsler-Reya, Robert, Zeid, Rhamy, Gibson, William J, Bandopadhayay, Pratiti,, Kieran, Mark W., Bradner, James E, Bradner, James E.,, Gibson, William J., Bolin, Sara, Cheshier, Samuel H, Liu, Kun-Wei, Schumacher, Steven E., Bergthold, Guillaume,, Cho, Yoon-Jae,, Beroukhim, Rameen,, Mitra, Siddhartha S., Weiss, William A, Nguyen, Brian, Beroukhim, Rameen, Schubert, Simone, Bandopadhayay, Pratiti, Schumacher, Steven E, Mitra, Siddhartha S, Gholamin, Sharareh, Bergthold, Guillaume, Yu, Furong, Qi, Jun, Tang, Yujie, Paolella, Brenton R, Vue, Nujsaubnusi, Kieran, Mark W, Masoud, Sabran, Swartling, Fredrik J.,   +38 more
core   +1 more source

Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia

Frontiers in Oncology, 2017
Acute myeloid leukemia (AML), a common hematological cancer of myeloid lineage cells, generally exhibits poor prognosis in the clinic and demands new treatment options.
Rui Lu, Rui Lu, Gang Greg Wang, Gang Greg Wang   +3 more
doaj   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi‐scenario applications, and translational prospects

Smart Molecules, EarlyView.
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Shuanglin Qin, Rui Peng, Guangshuai Zhang, Si Yan, Jin Xiao, Zishu Liu, Ziyu Tan, Qingqing Xie, Shangjie Li, Wei Luo, Xiaohe Xiao   +10 more
wiley   +1 more source